EP048: An Interview with Dr. Marshall Runge
Published on: 02/03/2026
Dr. Marshall Runge explains how GLP‑1 and GIP therapies lower A1C, reduce cardiovascular risk, and support sustainable weight loss, why compounded GLP‑1s aren’t equal to FDA drugs, and how prevention, muscle‑protecting exercise, and trusted primary care change outcomes.
The Diabetes Podcast Blog



